Newscast – Page 123 – media

Adoption of cloud-based imaging informatics tools set to accelerate

According to the Frost & Sullivan study, the total revenue of the global cloud-based medical imaging informatics market is expected to remain on a very strong growth trajectory over the next few years, growing from $285.4 million in 2016 to $830.5 million in 2021. That's a significant compound annual growth rate of 23.8 percent.
- Source: Healthcare IT news
- 481
- January 16, 2018
health IT imaging Market Views
Genentech beefs up its PD-L1 combo pipeline, signing the ‘don’t eat me’ specialists at Forty Seven

After expanding its partnership with Syndax $SNDX earlier this week on their lead drug, Genentech has beefed up their pipeline of PD-L1 combos with a fresh pact with Stanford spinout Forty Seven.
- Source: Endpts;
- 400
- January 15, 2018
Market Views PD-L1 combos
Alveo Closes $38 Million in Series A Financing to Create Accessible Diagnostics Devices

Alveo Technologies, Inc., ("Alveo" or "the Company") whose mission it is to create affordable and accessible infectious disease diagnostic devices, announced the closing of a $38 million Series A financing raised by Maxim Merchant Capital, a division of Maxim Group LLC. The round was oversubscribed and included existing and new investors. The offering proceeds will be used to advance the optimization and commercialization of Alveo's rapid diagnostic platform for infectious diseases.
- Source: Prnewswire
- 431
- January 15, 2018
infectious diseases Market Views Series
NHS to support 138 entrepreneurs on new medical technologies

The National Health Service (NHS) in the UK is set to support 138 entrepreneurs among its staff, through its clinical entrepreneurs’ programme, in the design and development of new healthcare technologies and innovations.
- Source: medicaldevice-network
- 658
- January 15, 2018
healthcare technologies and innovations NHS polices
New IVF technique hailed as the ‘most exciting advance in fertility treatment for 40 years’

A new IVF method that takes thousands of pictures of embryos to select the best eggs has increased the likelihood of a baby being born by 25 percent.
- Source: Daily Mail
- 536
- January 15, 2018
IVF pregnancy Researches
New AI system for lung cancer and heart disease

Artificial intelligence is gradually being adopted by health services to assist medics with the diagnosis of serious diseases. In one new development, scientists in Oxford, U.K. have launched an AI system for heart disease.
- Source: Digital Journal
- 992
- January 15, 2018
AI heart attacks lung cancer Researches
NHS Confed orders reports into NHS funding needs

The NHS Confederation has tasked the Institute for Fiscal Studies and the Health Foundation with analysing the funding needs of the UK’s health and care systems over the next 15 years.
- Source: pharmatimes
- 539
- January 12, 2018
health NHS polices
Depression medication initiation may lower oral antidiabetic drug adherence in diabetes

Adults with type 2 diabetes and major depressive disorders who begin using second-generation antipsychotics are more likely to have at least a 10% decline in oral antidiabetic drug use 180 to 365 days after initiation compared with nonusers of second-generation antipsychotics, according to a study.
- Source: Healio
- 659
- January 12, 2018
antipsychotics diabetes Researches
Sex hormone-binding globulin associated with androgen deficiency

Higher levels of sex hormone-binding globulin were associated with androgen deficiency in men, independent of total testosterone level, researchers in Italy reported.
- Source: healio
- 456
- January 12, 2018
androgen deficiency Researches sex hormone
Celgene to Acquire Impact Biomedicines, Adding Fedratinib to Its Pipeline of Novel Therapies for Hematologic Malignancies

Celgene Corporation (CELG) and Impact Biomedicines today announced the signing of a definitive agreement in which Celgene will acquire Impact Biomedicines, which is developing fedratinib for myelofibrosis and polycythemia vera. Under the terms of the agreement, Celgene will pay approximately $1.1 billion upfront and up to $1.25 billion in contingent payments based on regulatory approval milestones for myelofibrosis. Additional future payments for regulatory approvals in additional indications and sales-based milestones are also possible.
- Source: finance.yahoo
- 539
- January 12, 2018
Celgene FDA Fedratinib Impact Market Views myelofibrosis

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.